eXoZymes closes $6M public offering of stock and warrants

eXoZymes Inc. (NASDAQ: EXOZ) announced the closing of an underwritten public offering of common stock and warrants, raising approximately $5.95 million in gross proceeds before deducting underwriting discounts, commissions, and estimated offering expenses.

The offering consisted of 330,575 units, including 34,440 units sold through partial exercise of an over-allotment option. Each unit comprised two shares of common stock and one warrant to purchase one additional share. The public offering price was $8.99 per share and $0.02 per warrant.

The warrants become exercisable one year from issuance at an exercise price of $11.24 per share and expire on the five-year anniversary of the issuance date. The warrants are not listed on any national securities exchange. The warrant exercise price may be reset to $0.001 if the company sells additional shares or convertible securities at a per-share price below $8.99 in a public or private offering before June 5, 2027.

The company stated it intends to use net proceeds to support development and commercialization of N-trans-caffeoyltyramine, advance additional product opportunities, fund research and development, and for working capital and general corporate purposes.

MDB Capital acted as sole book-running manager. The securities were offered under a shelf registration statement on Form S-3 declared effective by the U.S. Securities and Exchange Commission on January 23, 2026. A final prospectus supplement was filed with the SEC on June 8, 2026.

eXoZymes, founded in 2019, develops bioengineered enzymes for producing nutraceuticals and medicines from biological feedstocks.

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• China Pharma prices $5 million direct offering at $2 per share
• Progress Software to acquire Domo's assets for $400 million in cash